Related Experiment Video
Updated: Jul 16, 2026

10:14
Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
Published on: May 26, 2023
The macular automated photostress test
Mandeep Singh Dhalla1, Aldo Fantin, Kevin J Blinder
1Barnes Retina Institute, St Louis, Missouri, USA. Mandeep.S.Dhalla@gmail.com <Mandeep.S.Dhalla@gmail.com>
American Journal of Ophthalmology
|February 17, 2007
Summary
The new automated macular photostress (MAP) test quantifies macular disease severity and aids in differentiating optic nerve damage from macular conditions. This noninvasive test shows significant changes in macular disease but not in optic nerve pathology.
Area of Science:
- Ophthalmology
- Visual Science
Background:
- Age-related macular degeneration (AMD) and primary open-angle glaucoma (POAG) are leading causes of vision loss.
- Accurate diagnosis and severity assessment are crucial for effective management of these conditions.
Purpose of the Study:
- To introduce a standardized macular automated photostress (MAP) test using an automated perimeter.
- To evaluate its utility in quantifying macular disease severity.
- To assess its ability to distinguish optic neuropathy from macular pathology.
Main Methods:
- A prospective interventional pilot study involving 25 pseudophakic subjects (65-84 years old).
- Participants included patients with non-neovascular AMD, healthy controls, and patients with POAG.
- Foveal threshold testing was performed using an automated perimeter, measuring baseline sensitivity, photostress-induced depression, and recovery time.
Main Results:
- Automated macular photostress testing demonstrated a significant decrease in foveal sensitivity (P < .001) and delayed recovery in patients with AMD.
- The foveal response curve remained unaffected in patients with POAG (P = .343), indicating no significant impact from optic nerve pathology.
Conclusions:
- The macular automated photostress (MAP) test is a cost-effective, noninvasive tool for assessing macular disease.
- This standardized protocol objectively defines disease severity and can monitor treatment response.
- The MAP test aids in differentiating optic neuropathy from macular pathology.

